Market Newsdesk

SAN FRANCISCO, July 09, 2026 (GLOBE NEWSWIRE) — Girard Sharp LLP, a national investment, securities, and consumer class action firm, is investigating potential securities claims on behalf of former Berry Global Group, Inc (“Berry”) investors who received shares of Amcor plc (“Amcor” or the “Company”) in connection with Amcor’s acquisition of Berry on April 30, 2025 (“Merger”).

AMCOR STOCK DECLINES FOLLOWING APRIL 2025 MERGER

Amcor is a Switzerland–based global packaging company that develops and manufactures packaging solutions across a wide range of market segments, including healthcare, agriculture, and food service. The Company states, “As a global leader in packaging solutions for consumer and healthcare products, our industry-leading innovation capabilities, global scale and technical expertise help our customers grow and meet the needs of millions of consumers every day.” Since the closing of the Merger, the Company’s stock price has declined in value.

If you are a former Berry Global investor with losses, please

fill out this form

, email

[email protected]

, or call (866) 981-4800 for a free consultation. 

Why Girard Sharp? 

Girard Sharp represents investors, consumers, and institutions in class actions and other complex litigation nationwide. We recently obtained a $36.5 million securities settlement against Maxar Technologies, a space imagery company, after its share price collapsed following its acquisition of DigitalGlobe. Our attorneys have obtained multimillion-dollar recoveries for victims of unfair and deceptive practices in antitrust, financial fraud, and consumer protection matters against some of the country’s largest corporations, including Raymond James, John Hancock, and Sears. Girard Sharp has earned top-tier rankings from U.S. News and World Report for Securities and Class Action Litigation and has been repeatedly selected as an Elite Trial Lawyers finalist by the National Law Journal. 

Contact 

Girard Sharp LLP
(866) 981-4800
[email protected]
[email protected]
www.girardsharp.com

METTAWA, Ill., July 09, 2026 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) will release its 2026 second quarter financial results on Thursday, July 30, 2026, before the market opens by way of an advisory release, notifying the public that the complete and full-text results will be available on the Company’s website. The results will also be available on the SEC’s website with the Form 8-K filing of the release.

The Company will hold a conference call at 10 a.m. CT / 11 a.m. ET, Thursday, July 30, 2026, hosted by David M. Foulkes, chairman and chief executive officer, Ryan M. Gwillim, executive vice president, chief financial officer, and chief strategy officer, and Stephen Weiland, senior vice president, finance and deputy CFO. A copy of the presentation to be used on this call will be available when the results are released as noted above.

The webcast can be accessed at Brunswick.com and here: Webcast | Brunswick Corporation Q2 2026 Earnings Conference Call

Security analysts and investors wishing to participate via telephone should call 877-900-9524 (no password needed). Callers outside of North America should call 412-902-0029 (no password needed) to be connected. These numbers can be accessed 15 minutes before the call begins, as well as during the call.

To listen via the Internet, go to www.brunswick.com/investors.  Please go to the website at least 15 minutes before the call to register, download, and install any audio software needed. 

A replay of the conference call will be available through 1 p.m. CT Thursday August 6, 2026, by calling 877-660-6853 or 201-612-7415 (Access ID: 13761336). The replay also will be available at  www.brunswick.com/investors.

About Brunswick Corporation

Brunswick Corporation (NYSE: BC) is a global leader in marine recreation, delivering innovation that transforms experiences on the water and beyond. Its technology-driven solutions are informed by deep consumer insights and guided by the belief that “Next Never Rests™.” Brunswick is home to more than 60 industry-leading brands across marine propulsion (including Mercury Marine), parts and accessories (including Attwood), and marine electronics (including Simrad and Lowrance), as well as boat brands including Boston Whaler, Sea Ray, Bayliner, Lund, and Harris. Headquartered in Mettawa, Illinois, Brunswick has approximately 14,000 employees operating in 26 countries. Learn more at Brunswick.com.

Forward-Looking Statements

Certain statements in this news release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations, estimates, and projections about Brunswick’s business and by their nature address matters that are, to different degrees, uncertain. Words such as “may,” “could,” “should,” “will,” “expect,” “anticipate,” “project,” “position,” “intend,” “target,” “plan,” “seek,” “estimate,” “believe,” “predict,” “outlook,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties that may cause actual results to differ materially from expectations as of the date of this news release. These risks include, but are not limited to: the effect of adverse general economic conditions, including rising interest rates, and the amount of disposable income consumers have available for discretionary spending; changes to trade policy and tariffs, including retaliatory tariffs; fiscal and monetary policy changes; adverse capital market conditions; changes in currency exchange rates; competitive pricing pressures; higher energy and fuel costs; managing our manufacturing footprint and operations; loss of key customers; international business risks, geopolitical tensions or conflicts, sanctions, embargoes, or other regulations; actual or anticipated increases in costs, disruptions of supply, or defects in raw materials, parts, or components we purchase from third parties; supplier manufacturing constraints, increased demand for shipping carriers, and transportation disruptions; adverse weather conditions, climate change events and other catastrophic event risks; our ability to develop new and innovative products and services at a competitive price; absorbing fixed costs in production; our ability to meet demand in a rapidly changing environment; public health emergencies or pandemics; our ability to successfully implement our strategic plan and growth initiatives; attracting and retaining skilled labor, implementing succession plans for key leadership and executing organizational and leadership changes; our ability to integrate acquisitions and the risk for associated disruption to our business; the risk that restructuring or strategic divestitures will not provide business benefits; our ability to identify and complete targeted acquisitions; maintaining effective distribution; dealer and customer ability to access adequate financing; inventory reductions by dealers, retailers, or independent boat builders; requirements for us to repurchase inventory; risks related to the Freedom Boat Club franchise business model; outages, breaches, or other cybersecurity events regarding our technology systems, which have affected and could further affect manufacturing and business operations and could result in lost or stolen information and associated remediation costs; our ability to protect our brands and intellectual property; an impairment to the value of goodwill and other assets; product liability, warranty, and other claims risks; legal, environmental, and other regulatory compliance, including increased costs, fines, and reputational risks; risks associated with joint ventures that do not operate solely for our benefit; changes in income tax legislation or enforcement; managing our share repurchases; and risks associated with certain divisive shareholder activist actions.

Additional risk factors are included in the Company’s Annual Report on Form 10-K for 2025 and in subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date on which they are made, and Brunswick does not undertake any obligation to update them to reflect events or circumstances after the date of this news release.

STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01 in Europe.

All European and US Sites to Treat Patients with Commercially Manufactured GP2

The Company previously announced that the first three commercial lots of GP2 active ingredient were manufactured in 2023 in an approved commercial facility, which could be used to prepare approximately 200,000 doses of GP2. In 2024, the first commercial lot filling GP2 into vials for commercial sale or for clinical use was manufactured in a commercial facility. In addition, drug stability programs were initiated for all four lots. Data on these commercial lots was submitted to the FDA, and after review, the first commercial lot of GP2 vials was approved for use in FLAMINGO-01 in the US in early 2026. All approximately 40-50 US sites have been supplied with commercially manufactured GP2 vials and have begun treating patients with these vials. We were able to efficiently distribute the GP2 vials and communicate with the US pharmacists working with our warehouse partners and through our clinical team, which we internalized in Q4 2025.

The European Medicines Agency (EMA) has completed their review and will also allow use of the same commercially manufactured GP2 lot in FLAMINGO-01 in Europe. Thus, all clinical sites in the US and Europe, which have increased from 160 sites to approximately 170-180 sites, are expected to be using the same lot with shipments to European pharmacies already under way. We are now seeking approval to use this lot in the UK and Canada in separate and independent regulatory processes.

About FLAMINGO-01 Open Label Phase III Data

More than 1,300 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data than the approximately 50 patients treated in the Phase IIb trial. The Primary Immunization Series (PIS), which includes the first 6 GLSI-100 injections over the first 6 months and is required to reach peak protection, is followed by 5 booster injections given every 6 months to prolong the immune response, thereby providing longer-term protection.

• In the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the PIS is completed shows an approximately 70-80% reduction in recurrence rate.
• This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.
• The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.
  • The AACR Meeting 2026 delayed-type-hypersensitivity (DTH) poster and the ASCO Meeting 2026 injection site reaction (ISR) poster can be seen and downloaded at the bottom of the Phase III clinical trial tab on the Company’s website here.
  • As shown in both posters the frequency of DTH and ISR reactions increased statistically significantly over time.
  • As reported in Table 1 of each poster, each HLA-A type exhibited more frequent immune reactivity after treatment with GLSI-100 than at baseline.
  • Baseline DTH reaction prior to any treatment suggests that GP2 may be a natural antigen and that GP2 specific T cells may exist in some patients prior to any treatment with GLSI-100. Baseline immune response to GP2 prior to any vaccination with GP2 was also observed in the Phase IIb trial and is being observed in the blinded randomized arms of FLAMINGO-01, where HLA-A*02 only patients are being vaccinated.

Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.

About GLSI-100 Phase IIb Study

In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A*02 breast cancer patients, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were treated with GM-CSF alone. After 5 years of follow-up, there was an 80% or greater reduction in cancer recurrences in the HER2/neu 3+ patients who were treated with GLSI-100, followed, and remained disease free over the first 6 months, which we believe is the time required to reach peak immunity and thus maximum efficacy and protection. The Phase IIb posters and results can be summarized as follows and can be seen here:

• 80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile.
• The PIS elicited a potent immune response as measured by local skin tests and immunological assays.

About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of Fast Track designated GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 170-180 sites globally.

For more information on FLAMINGO-01, please visit the Company’s website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the “Contacts and Locations” section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: [email protected]

About Breast Cancer and HER2/

neu

Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in Greenwich LifeSciences’ Annual Report on the most recent Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Company Contact

Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: [email protected]

Investor & Public Relations Contact for Greenwich LifeSciences

Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: [email protected]

VANCOUVER, British Columbia, July 09, 2026 (GLOBE NEWSWIRE) — Equinox Gold Corp. (TSX: EQX, NYSE American: EQX) (“Equinox Gold” or the “Company”) is pleased to announce production results for the three months ended June 30, 2026 (“Q2” or the “Quarter”), along with an update on operations at its two Canadian cornerstone assets: Valentine Gold Mine (“Valentine”) in Newfoundland & Labrador and Greenstone Gold Mine (“Greenstone”) in Ontario. All dollar figures are in United States dollars unless otherwise noted.

Darren Hall, CEO of Equinox Gold, commented: “Equinox Gold delivered sequentially higher production at its Canadian operations with 97,273 ounces (“oz”) of combined gold production from Greenstone and Valentine, contributing to consolidated quarterly production of 176,836 ounces. Production from our Canadian operations continues to steadily increase with notable performance indicators highlighting progress in the ramp-up of our two long-life, Canadian mines. The team’s continued focus on operational execution and optimization is delivering results at both Greenstone and Valentine as we move into what we expect to be a stronger second half of the year.

“At Greenstone, mining rates averaged more than 199,000 tonnes per day following the winter months, while mill throughput averaged 26,856 tonnes per day. Importantly, we continue to see a growing number of days operating above nameplate capacity, with 69% of days exceeding 27,000 tonnes per day compared to 51% in the first quarter. This trend is anticipated to continue into the second half of the year resulting in expected higher production quarter over quarter for the balance of the year. At Valentine, the process plant averaged 7,730 tpd, or 113% of nameplate. We expect to see increasing production in the second half of the year, driven by higher mill feed grades and continued strong plant performance, with Phase 2 mill expansion early works expected to begin during H2 2026.

“The quarter also marked two important strategic milestones. We announced our proposed business combination with Orla Mining, which we believe will create a premier North American gold producer with approximately 1.1 million ounces of expected annual gold production in 2026, a funded pathway to approximately 1.9 million ounces of annual production over time, and a portfolio of high-quality, long-life assets capable of generating meaningful free cash flow and long-term value for shareholders.

“We also secured 20-year land access agreements with the three communities that host the multi-million-ounce Los Filos mine, a significant step towards the unlocking of value of this high-quality long-term growth asset in our portfolio. In addition to securing long-term land access, we established a new framework governing labour and supply services that reflects a more disciplined, transparent and sustainable operating model. We have initiated restart planning while advancing technical work to optimize the operation, including evaluating a rightsized carbon-in-leach development scenario. We believe Los Filos has the potential to become another high-quality, cornerstone asset within our portfolio and a meaningful contributor to Equinox Gold’s long-term growth.

“As we move into the second half of 2026, our priorities remain clear: continue delivering operational improvements at Greenstone and Valentine, advance and close the proposed combination with Orla Mining, progress the restart and long-term development plans for Los Filos, and execute on the organic growth opportunities across our portfolio. We believe these initiatives position Equinox Gold to continue strengthening its operating performance while creating substantial long-term value for shareholders.”

Highlights

• Produced 176,836 ounces (“oz”) of gold during Q2, including 64,656 oz from Greenstone, 32,617 oz from Valentine, 18,572 oz from Mesquite, 59,476 oz from Nicaragua, and 1,515 oz from Castle Mountain.
• Consolidated year-to-date gold production of 374,464 oz keeping the Company on track to achieve its 2026 gold production guidance of 700,000 to 800,000 oz.
• Announced a business combination with Orla Mining to create North America’s new senior gold producer with approximately 1.1 million ounces of expected annual gold production¹ in 2026 anchored by three Canadian gold mines, and a path toward more than 1.9 million ounces of annual gold production² from an internally funded North American growth pipeline (see May 13, 2026 news release).
• Secured 20-year land access agreements with all three communities at Los Filos and initiated restart activities (see June 25, 2026 news release). 
   

Q2 2026 Conference Call Details

Equinox Gold will release its unaudited financial and operating results for the three and six months ended June 30, 2026 on Wednesday, August 5, 2026 after market close. The Company will host a conference call and webcast to discuss the results on Thursday, August 6, 2026 commencing at 7:00am PT (10:00am ET). The webcast will be available for replay on Equinox Gold’s website until February 6, 2027.

Special Meeting of Shareholders to be held on July 22, 2026

Equinox Gold will hold its Special Meeting of Shareholders (“Meeting”) on Wednesday, July 22, 2026 commencing at 9:00am PT. At the Meeting, Equinox Gold shareholders will be asked to vote on an ordinary resolution authorizing and approving the issuance of up to 421,770,377 common shares of Equinox Gold in connection with the proposed acquisition by the Company of all the outstanding common shares of Orla Mining (TSX: OLA, NYSE-A: ORLA). Under the terms of the agreement, each Orla share will be exchanged for 1.00 Equinox Gold common share and US$0.0001 in cash. The deadline for voting by proxy is 9:00 am (Vancouver time) on July 20, 2026.

Meeting materials have been mailed to shareholders (“Meeting Materials”) and can also be downloaded at www.equinoxgold.com/shareholder-events and from Equinox Gold’s profile on SEDAR+ and EDGAR (see June 23, 2026 news release). Upon receipt of the Meeting Materials, which contain personalized voting information, shareholders can vote their shares online, by telephone or by mail, or can attend the Meeting and vote in person. Shareholders who cannot attend in person are invited to join an online webcast; however, the webcast is being provided for viewing purposes only. There will be no ability to vote via the webcast.

Shareholder Questions & Voting Assistance

Equinox Gold has retained Laurel Hill Advisory Group (“Laurel Hill”) to assist with shareholder communications and proxy solicitation in connection with the Meeting. If you have any questions before the Meeting about the proposed acquisition, Equinox Gold, the Meeting Materials or the voting process, please contact Laurel Hill by calling 1-877-452-7184 (North America toll-free) or 1-416-304-0211 (international), by texting “INFO” to either 1-877-452-7184 or 1-416-304-0211, or by email at [email protected].

About Equinox Gold

Equinox Gold (TSX: EQX, NYSE-A: EQX) is a Canadian mining company positioned for growth with a strong foundation of high-quality, long-life gold operations in Canada and across the Americas, and a pipeline of development and expansion projects. Founded and chaired by renowned mining entrepreneur Ross Beaty and guided by a seasoned leadership team with broad expertise, the Company is focused on disciplined execution, operational excellence and long-term value creation. Equinox Gold offers investors meaningful exposure to gold with a diversified portfolio and clear path to growth. Learn more at www.equinoxgold.com or contact [email protected].

Equinox Gold Contact

Ryan King

Executive Vice President, Capital Markets
T: 778.998.3700
E: [email protected]
E: [email protected]

Qualified Person & Technical Information

The scientific and technical information contained in this news release was approved by Matthew MacPhail, P.Eng., Senior Vice President Business Planning and Technical Services for Equinox Gold and a “Qualified Person” under National Instrument 43-101.

Cautionary Notes & Forward-looking Information


This news release includes forward-looking information and forward-looking statements within the meaning of applicable securities laws and may include future-oriented financial information or financial outlook information (collectively “Forward-looking Information”). Actual results of operations and the ensuing financial results may vary materially from the amounts set out in any Forward-looking Information. Forward-looking Information in this news release includes: the Company’s strategic vision and expectations for exploration potential, production capabilities, growth potential, expansion projects and future financial or operating performance, including shareholder returns; expectations for Greenstone and Valentine operations, including achieving design capacity and anticipated production; production and cost guidance; potential future mining opportunities around Valentine; potential for the Phase 2 expansion at Valentine; higher mill feed grades and stronger plant performance at Valentine; completion of the combination with Orla, including an approval at the Special Meeting of Shareholders; anticipated timing and development of Castle Mountain Phase 2; and the potential for a restart of operations at Los Filos. Forward-looking Information is typically identified by use of words such as “will”, “growth”, “increase”, “expect”, ”achieve”, “anticipate”, “deliver”, “continue” and “progress” and similar expressions and phrases or statements that certain actions, events or results “may”, “could”, or “should”, or the negative connotation of such terms, are intended to identify Forward-looking Information. While the Company believes these expectations are reasonable, they are not guarantees and undue reliance should not be placed on them. Forward-looking Information is based on the Company’s current expectations and assumptions, including: achievement of exploration, production, cost and development goals; ramping up and achieving design capacity at Valentine and Greenstone; timely execution of Castle Mountain permitting and initiation of Phase 2 construction, including receipt of required approvals and permits and effectiveness of the Fast-41 Program; approval for and initiation of the Valentine Phase 2 expansion; stable gold prices and input costs; availability of funding, accuracy of Mineral Reserve and Mineral Resource estimates; successful long-term agreements with Los Filos communities, management of suspended operations and the potential of restarting operations; adherence to mine plans and schedules, expected ore grades and recoveries; absence of labour disruptions or unplanned delays; productive relationships with works, union and communities; maintenance of and timely receipt of permits and regulatory approvals; compliance with environmental and safety regulations; and constructive engagement with Indigenous and community partners. While the Company considers these assumptions reasonable, they may prove incorrect.

Forward-looking Information involves numerous risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such Forward-looking Information. Such factors include those described in the section titled “Risk Factors” in the Company’s MD&A dated February 20, 2026 for the year ended December 31, 2025, and in the section titled “Risks Related to the Business” in Equinox Gold’s most recently filed Annual Information Form, both of which are available on SEDAR+ at 

www.sedarplus.ca
, on EDGAR at www.sec.gov/edgar and on Equinox Gold’s website at www.equinoxgold.com. Forward-looking Information reflects management’s current expectations for future events and is subject to change. Except as required by applicable law, the Company assumes no obligation to update or to publicly announce the results of any change to any Forward-looking Information contained or incorporated by reference to reflect actual results, future events or developments, changes in assumptions or other factors affecting Forward-looking Information. If the Company updates any Forward-looking Information, no inference should be drawn that the Company will make additional updates with respect to those or other Forward-looking Information. All Forward-looking Information contained in this news release is expressly qualified by this cautionary statement.

_______________________________

<sub><sup>1. Mid-point of Equinox Gold’s and Orla’s 2026 guidance, on a full-year basis, as further detailed in the Equinox Gold news release dated January 14, 2026 and the Orla news release dated January 20, 2026, respectively.



2.
Anticipated production growth comes from completion of the Valentine Phase 2 expansion (Canada) and with Castle Mountain (USA), South Railroad (USA), Los Filos (Mexico) and Camino Rojo underground (Mexico) in production and operating in line with expectations outlined in current technical reports, which technical reports are available under the respective SEDAR+ profiles of Equinox Gold (in the case of Valentine, Castle Mountain and Los Filos) and Orla (in the case of South Railroad and Camino Rojo).</sup></sub>